The Hb increase observed in our study was lower than the median increase of 2.3–2.5 g/dL reported by Gangat et al.[11] and Liu et al.[13], a discrepancy that may stem from their focus on patients with confirmed SGLT-2 inhibitor-associated erythrocytosis, potentially enriching their cohort with individuals showing more pronounced responses. This evidence concerns the gene GSTM1 and polycythemia.